由ADCY5引起的混合运动障碍 致病变体成功用咖啡因治疗:来自乌克兰的病例
Eugenia Tsoma1,2, Taras Studeniak3, Robert Jech2
1Department of Family Medicine and Outpatient Care, Second Faculty of Medicine, Uzhhorod National University, Uzhhorod, Ukraine.
Case reports in neurological medicine
|March 9, 2026
概括
咖啡因有效地管理了由于ADCY5基因变异 (MxMD-ADCY5) 引起的混合运动障碍患者的 Paroxysmal Dyskinesia. 高剂量咖啡因治疗在六个月内显著改善,没有任何不良影响.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于ADCY5基因 (MxMD-ADCY5) 的致病变异引起的混合运动障碍是罕见的.
- 它的特点是表现为合体形动作, dystonia, myoclonus,语音障碍和发育迟缓.
- 有限的治疗选择存在,但咖啡因对控制运动障碍有希望.
研究的目的:
- 报告一个MxMD-ADCY5病例,对咖啡因有显著反应.
- 介绍第一个报告的乌克兰患者与MxMD-ADCY5治疗高剂量咖啡因.
- 为了突出咖啡因在治疗 Paroxysmal Dyskinesia 的治疗潜力.
主要方法:
- 临床病例报告.
- 使用高剂量的咖啡因 (每天600毫克).
- 随访时间至少为6个月.
主要成果:
- 在 Paroxysmal Dyskinesia 中观察到显著的临床改善.
- 在成人患者中对咖啡因的高治疗反应.
- 在随访期间没有报告任何不良事件或副作用.
结论:
- 高剂量的咖啡因 (每天600毫克) 是MxMD-ADCY5.5的安全有效治疗方法.
- 咖啡因显著改善了乌克兰患者的症状.
- 这一案例支持咖啡因作为一种可行的治疗选择,用于管理MxMD-ADCY5.5.在MxMD-ADCY5.5.的运动障碍.
相关概念视频
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Gastrointestinal Motility Disorders
1.6K
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
1.6K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
2.0K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
2.0K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.2K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.2K
Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Huntington Disease l: Introduction
166
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
166


